Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “T790M”

109 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 109 results

Testing effectiveness (Phase 2)Study completedNCT03543683
What this trial is testing

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Who this might be right for
Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 115
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT03452592
What this trial is testing

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Who this might be right for
Advanced NSCLC Patients With T790M
Allist Pharmaceuticals, Inc. 220
Large-scale testing (Phase 3)UnknownNCT01579630
What this trial is testing

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

Who this might be right for
NSCLC
Taipei Veterans General Hospital, Taiwan 52
Testing effectiveness (Phase 2)UnknownNCT03758287
What this trial is testing

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Who this might be right for
Non-small Cell Lung Cancer
Sunshine Lake Pharma Co., Ltd. 158
Testing effectiveness (Phase 2)Looking for participantsNCT06277674
What this trial is testing

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Guangzhou University of Traditional Chinese Medicine 20
Testing effectiveness (Phase 2)UnknownNCT03257124
What this trial is testing

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Who this might be right for
Non-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase Inhibitors
Samsung Medical Center 80
Testing effectiveness (Phase 2)Study completedNCT02094261
What this trial is testing

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 210
Not applicableStudy completedNCT03363139
What this trial is testing

T790M Mutation Testing in Blood by Different Methodologies

Who this might be right for
NSCLC Stage IV
Spanish Lung Cancer Group 72
Large-scale testing (Phase 3)UnknownNCT02972333
What this trial is testing

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Who this might be right for
EGFR-TKI Resistant MutationNonsmall Cell Lung CancerAZD9291+1 more
Shandong Cancer Hospital and Institute 150
Testing effectiveness (Phase 2)UnknownNCT05458726
What this trial is testing

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Who this might be right for
EGFR T790MOsimertinibNon-small Cell Lung Cancer+1 more
Peking Union Medical College 80
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Large-scale testing (Phase 3)Study completedNCT02474355
What this trial is testing

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 3,017
Testing effectiveness (Phase 2)Study completedNCT02759835
What this trial is testing

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Who this might be right for
Lung AdenocarcinomaLung Neoplasms
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)UnknownNCT02330367
What this trial is testing

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Who this might be right for
Metastatic Non-small Cell Lung Cancer
Hangzhou ACEA Pharmaceutical Research Co., Ltd. 368
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)Study completedNCT03228277
What this trial is testing

Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA

Who this might be right for
Non Small Cell Lung Cancer
Konkuk University Medical Center 25
Testing effectiveness (Phase 2)UnknownNCT03706287
What this trial is testing

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Who this might be right for
Lung Cancer Metastatic
Sichuan Cancer Hospital and Research Institute 62
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Load More Results